Clinical and Cognitive Correlates of Amyloid‐Related Imaging Abnormalities During Lecanemab Treatment in Early Alzheimer's Disease

In this real-world cohort, symptomatic ARIA-particularly ARIA-H-was associated with measurable cognitive decline. While most ARIA cases were asymptomatic and did not impact cognition, these findings highlight the need for routine neuroimaging surveillance and individualized treatment strategies to optimize safety and cognitive outcomes during Lecanemab therapy. This highlights the need for ongoing assessment of ARIA in clinical practice to enhance the safety and efficacy of amyloid-targeting therapies in early AD.